Researchers at Inovio Pharmaceuticals is a biotech company in Pennsylvania in the United States, have claimed that a small trial of the coronavirus vaccine has yielded positive results.
Researchers at the institute say 34 of the 36 people tested on their vaccine body’s positive immune system have been found to have ‘immunological response rates’. They are trying to find an urgent solution to the coronavirus epidemic. The work of making the vaccine is progressing fast.
At the beginning of the coronavirus epidemic, Inovio announced the development of a vaccine. The company’s share price has risen to $4.5 billion. Although Inovio reported positive results from their vaccine test yesterday, it did not disclose details of whether the vaccine was effective.
How many patients have developed antibodies by inactivating coronavirus in vaccine tests on behalf of the organization, They did not inform. Whether Covid-19 can be protected from infection, This information is important in that case.
Shares of Inovio rose 10-fold when it announced plans to develop a vaccine at the start of the coronavirus outbreak. The company has not yet released any clinical information. The company was valued at 300 million this year, which has now risen to more than $4.5 billion. Their share price has fallen 13 percent since the announcement of the results of the vaccine yesterday.
According to the US health website Stat, One study points out that Inovio Pharmaceuticals neutralizing antibodies are not important. So it has been found that identifiable antibodies are not found in the blood of one-third of people who recover from covid19.
Katherine Edwards, scientific director of the Vanderbilt Vaccine Research Program in Nashville, said the Inovio vaccine looks safe for further testing. However, it is difficult to say whether it is beneficial without more detailed information on the effectiveness of the patient.
Since the outbreak of the coronavirus epidemic, various organizations have come up with the idea of making vaccines. Details of clinical trials of these vaccines are not disclosed. Moderna pharmaceuticals in the United States, which has been leading the race to develop vaccines since last month, The detailed results of the vaccine have been criticized for not being published.
On May 16, Moderna released the preliminary results of their first-stage test. The issue made headlines in various media. The company’s share price rose. Anthony S. Fauci, the top infectious disease specialist in the United States and director of the National Institute of Allergy and Infectious Diseases, described the results of the Moderna vaccine test as “very promising.” But, he told Stat News that he did not like the way the organization published their information.
“From the point of view of neutral antibodies, the initial information from the company seems very promising,” Anthony Fauci said in an interview with State News on Monday. However, I did not like the way they increased the share price earlier without disclosing full details. ‘
In the case of the release of the vaccine results, Moderna was revealed how many antibodies were produced in the patient’s body. Moderna and Inovio have promised to publish their peer-reviewed information in medical journals.